Welcome : Guest

Fibrogen, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Fibrogen, Inc., which is principally involved in Research-Based Biopharmaceuticals Business. Illustrated with 17 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-64351
Price: $850
Company Type: Public
Pages: 22
Date: November 2016
Market Data Tables: 17

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: FibroGen, Inc.’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for Europe, Japan-Related Party, and All Others......2
Kidney Disease Drugs......7
Table 2: Traditional Chinese Medicine (TCM) Market for Kidney Ailments by Drug in China (2015) - Percentage Share Breakdown by Value Sales for Ambrette Capsule, Haikunshenxi Capsule, Shenyankangfu Tablet, Uremic Clearance Granule, Yinhuamiyangling and Others......7
Table 3: Kidney Disease Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp and Others......8
Table 4: Dialysis Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp, EPO alfa/beta biosimilars and Others......9
Table 5: Hemodialysis Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp, Epogen, and Others......10
Table 6: Chronic Kidney Disease Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp and Others......11
Table 7: Peritoneal Dialysis Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp, Epogen, and Others (Includes Mircera)......12
Table 8: New Patients with Kidney Failure by Cause in the US (2015) - Percentage Share Breakdown by Volume for Diabetes, High Blood Pressure and Others......13
Chronic Obstructive Pulmonary Disease (COPD) Drugs......14
Table 9: Chronic Obstructive Pulmonary Disease (COPD) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for Europe, North America and Rest of the World......14
Table 10: Chronic Obstructive Pulmonary Disease (COPD) Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Long Acting Muscarinic Antagonists (LAMA), Long Acting Muscarinic Antagonists (LAMA) and Long Acting β2-Agonists (LABA), and Long Acting β2-Agonists (LABA) and Inhaled Corticosteroid (ICS)......15
Table 11: No. of Chronic Obstructive Pulmonary Disease (COPD) Patients Worldwide (2015) - Percentage Market Share Breakdown for Europe, North America, and Rest of World......16
Table 12: Chronic Obstructive Pulmonary Disease (COPD) and Asthma Market by Product Worldwide (2015) - Percentage Share Breakdown by Value for Flixotide and Flovent, Seretide and Advair, Spiriva, Symbicort, Xolair, and Others......17
Liver Cancer Patients......18
Table 13: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......18
HBV/HCV Therapeutics......19
Table 14: Market Shares of Leading HBV/HCV Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., and Others......19
Table 15: Market Shares of Leading Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Co (BMY), GlaxoSmithKline Plc (GSK), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Vertex Pharmaceuticals, Inc. (VRTX), and Others......20
Table 16: FibroGen, Inc.’s Sales by Geographic Region Worldwide (2013-2014) in Percentage for Europe, Japan-Related Party and All Other......21
Table 17: FibroGen, Inc.’s Revenues by Category Worldwide (2013-2014) in Percentage for License and Milestone Revenue and Collaboration Services and Other Revenue......22